Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Combination of cancer-specific prodrug nanoparticle with Bcl-2 inhibitor to overcome acquired drug resistance
Jinseong Kim, Man Kyu Shim, Suah Yang, et al.
Journal of Controlled Release (2020) Vol. 330, pp. 920-932
Closed Access | Times Cited: 54

Showing 1-25 of 54 citing articles:

Tumor-activated carrier-free prodrug nanoparticles for targeted cancer Immunotherapy: Preclinical evidence for safe and effective drug delivery
Man Kyu Shim, Suah Yang, In‐Cheol Sun, et al.
Advanced Drug Delivery Reviews (2022) Vol. 183, pp. 114177-114177
Closed Access | Times Cited: 113
Targeted Delivery of Drugs and Genes Using Polymer Nanocarriers for Cancer Therapy
Wentao Xia, Zixuan Tao, Bin Zhu, et al.
International Journal of Molecular Sciences (2021) Vol. 22, Iss. 17, pp. 9118-9118
Open Access | Times Cited: 111
Cancer-activated doxorubicin prodrug nanoparticles induce preferential immune response with minimal doxorubicin-related toxicity
Suah Yang, Man Kyu Shim, Woo Jun Kim, et al.
Biomaterials (2021) Vol. 272, pp. 120791-120791
Closed Access | Times Cited: 109
Emerging Albumin-Binding Anticancer Drugs for Tumor-Targeted Drug Delivery: Current Understandings and Clinical Translation
Hanhee Cho, Seong Ik Jeon, Cheol‐Hee Ahn, et al.
Pharmaceutics (2022) Vol. 14, Iss. 4, pp. 728-728
Open Access | Times Cited: 69
Recent progress in nanotechnology-based drug carriers for resveratrol delivery
Chunhong Li, Zhen Wang, Hui Lei, et al.
Drug Delivery (2023) Vol. 30, Iss. 1
Open Access | Times Cited: 63
Therapeutic Silencing of BCL-2 Using NK Cell-Derived Exosomes as a Novel Therapeutic Approach in Breast Cancer
Kübra Kaban, Clemens Hinterleitner, Yanjun Zhou, et al.
Cancers (2021) Vol. 13, Iss. 10, pp. 2397-2397
Open Access | Times Cited: 60
Overcoming cancer therapy resistance: From drug innovation to therapeutics
Jinrui Wei, Meng‐Yi Lu, Tian‐Hua Wei, et al.
Drug Resistance Updates (2025) Vol. 81, pp. 101229-101229
Closed Access | Times Cited: 1
Oxidative stress in obesity-associated hepatocellular carcinoma: sources, signaling and therapeutic challenges
Manoja K. Brahma, Eduardo Hideo Gilglioni, Lang Zhou, et al.
Oncogene (2021) Vol. 40, Iss. 33, pp. 5155-5167
Open Access | Times Cited: 48
How Did Conventional Nanoparticle-Mediated Photothermal Therapy Become “Hot” in Combination with Cancer Immunotherapy?
Wan Su Yun, Ji‐Ho Park, Dong‐Kwon Lim, et al.
Cancers (2022) Vol. 14, Iss. 8, pp. 2044-2044
Open Access | Times Cited: 35
PEGylated reduced graphene oxide as nanoplatform for targeted gene and drug delivery
Erhan Demirel, Yasemin Yüksel Durmaz
European Polymer Journal (2023) Vol. 186, pp. 111841-111841
Closed Access | Times Cited: 19
Peptide-modified bioresponsive chondroitin sulfate micelles for targeted doxorubicin delivery in triple-negative breast cancer
Jingmou Yu, Liangliang Wang, Yun Ling, et al.
Colloids and Surfaces B Biointerfaces (2023) Vol. 227, pp. 113381-113381
Closed Access | Times Cited: 17
Co-delivery of siBcl-2 and PTX with mitochondria-targeted functions to overcoming multidrug resistance
Liqiao Zhang, Xinyu Cao, Jiayi Chen, et al.
International Journal of Pharmaceutics (2024) Vol. 654, pp. 123970-123970
Closed Access | Times Cited: 6
The safe and effective intraperitoneal chemotherapy with cathepsin B-specific doxorubicin prodrug nanoparticles in ovarian cancer with peritoneal carcinomatosis
Jinseong Kim, Man Kyu Shim, Young‐Jae Cho, et al.
Biomaterials (2021) Vol. 279, pp. 121189-121189
Closed Access | Times Cited: 40
Cancer cell-specific and pro-apoptotic SMAC peptide-doxorubicin conjugated prodrug encapsulated aposomes for synergistic cancer immunotherapy
Jinseong Kim, Man Kyu Shim, Yujeong Moon, et al.
Journal of Nanobiotechnology (2024) Vol. 22, Iss. 1
Open Access | Times Cited: 5
Multi-functional nanomedicines for combinational cancer immunotherapy that transform cold tumors to hot tumors
Hanhee Cho, Kwangmeyung Kim
Expert Opinion on Drug Delivery (2024) Vol. 21, Iss. 4, pp. 627-638
Closed Access | Times Cited: 5
Rational design of peptides to overcome drug resistance by metabolic regulation
Min Sun, Le He, Ran Chen, et al.
Drug Resistance Updates (2025), pp. 101208-101208
Closed Access
Nanoscale strategies: doxorubicin resistance challenges and enhancing cancer therapy with advanced nanotechnological approaches
Jian Xin Lim, Yoke Keong Yong, Firli Rahmah Primula Dewi, et al.
Drug Delivery and Translational Research (2025)
Closed Access
Gene Drug Delivery for the Treatment of Cancer
Sunny Dhiman
IGI Global eBooks (2025), pp. 55-86
Closed Access
Rediscovery of nanoparticle-based therapeutics: boosting immunogenic cell death for potential application in cancer immunotherapy
Suah Yang, In‐Cheol Sun, Hee Sook Hwang, et al.
Journal of Materials Chemistry B (2021) Vol. 9, Iss. 19, pp. 3983-4001
Closed Access | Times Cited: 32
Beyond basic research: the contribution of cathepsin B to cancer development, diagnosis and therapy
Andrey A. Zamyatnin, Levy C Gregory, Paul A. Townsend, et al.
Expert Opinion on Therapeutic Targets (2022) Vol. 26, Iss. 11, pp. 963-977
Open Access | Times Cited: 21
Comparative study of cathepsin B-cleavable linkers for the optimal design of cathepsin B-specific doxorubicin prodrug nanoparticles for targeted cancer therapy
Nayeon Shim, Seong Ik Jeon, Suah Yang, et al.
Biomaterials (2022) Vol. 289, pp. 121806-121806
Closed Access | Times Cited: 20
Unlocking the Therapeutic Potential of BCL-2 Associated Protein Family: Exploring BCL-2 Inhibitors in Cancer Therapy
Bisan El Dakkak, Jalal Taneera, Waseem El‐Huneidi, et al.
Biomolecules & Therapeutics (2024) Vol. 32, Iss. 3, pp. 267-280
Open Access | Times Cited: 4
Ph/Gsh Dual-Responsive Janus-Type Au@H-Mp@Dox Mr Molecular Imaging Nanomotor for Combined Photothermal/Chemotherapeutic Treatment of Pancreatic Cancer
Hao Zhang, Dan Xie, Meng Chen, et al.
(2025)
Closed Access
Targeting of claudin-4 by Clostridium perfringens enterotoxin-conjugated polysialic acid nanoparticles for pancreatic cancer therapy
Man Kyu Shim, Jinhee Na, In Kyung Cho, et al.
Journal of Controlled Release (2021) Vol. 331, pp. 434-442
Closed Access | Times Cited: 25
Hierarchical drug release designed Au @PDA-PEG-MTX NPs for targeted delivery to breast cancer with combined photothermal-chemotherapy
Wen Li, Zhiwen Cao, Liuchunyang Yu, et al.
Journal of Nanobiotechnology (2021) Vol. 19, Iss. 1
Open Access | Times Cited: 24
Page 1 - Next Page

Scroll to top